ProMetic’s PBI-4050 Receives Orphan Drug Designation by the European Commission for Idiopathic Pulmonary Fibrosis Treatment
ProMetic Life Sciences, Inc., a biopharmaceutical company focused on plasma-derived therapeutics and small-molecule drug development, recently announced that its product PBI-4050 for the treatment of idiopathic pulmonary fibrosis (IPF) has been granted orphan drug designation status by the European Commission. IPF is a progressive fatal lung disease of unknown…